SCHEMBL16266972

SCHEMBL16266972

CC[C@@H](C(=O)O)N1Cc2ccccc2C1=O

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 3/20 0.72
MAPT P10636 2/20 0.72
SMN1; SMN2 Q16637 1/20 0.72
KDM4E B2RXH2 2/20 0.70
ALDH1A1 P00352 1/20 0.61
TSHR P16473 1/20 0.61
XIAP P98170 1/20 0.61
HKDC1 Q2TB90 1/20 0.61
HSD17B10 Q99714 1/20 0.61
TDP1 Q9NUW8 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
SDCBP O00560 5/20 0.59
SDC2 P34741 5/20 0.59
STAT3 P40763 1/20 0.58
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
HTR1A P08908 1/20 0.54
ADRA1A P35348 1/20 0.54
NPC1 O15118 1/20 0.54
RAB9A P51151 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20014221 1.00 ALOX15 (0.72) ALOX15MAPTSMN1; SMN2KDM4EALDH1A1
SCHEMBL16266975 1.00 ALOX15 (0.72) ALOX15MAPTSMN1; SMN2KDM4EALDH1A1
SCHEMBL16267065 0.89 ALOX15 (0.74) ALOX15MAPTSMN1; SMN2KDM4EALDH1A1
SCHEMBL16267064 0.89 ALOX15 (0.74) ALOX15MAPTSMN1; SMN2KDM4EALDH1A1
SCHEMBL20116492 0.87 ALOX15 (0.74) ALOX15MAPTSMN1; SMN2KDM4EALDH1A1
SCHEMBL30506288 0.87 ALOX15 (0.74) ALOX15MAPTSMN1; SMN2KDM4EALDH1A1
SCHEMBL7415930 0.86 ALOX15 (0.69) ALOX15MAPTSMN1; SMN2KDM4EALDH1A1
SCHEMBL7415929 0.86 ALOX15 (0.69) ALOX15MAPTSMN1; SMN2KDM4EALDH1A1
SCHEMBL24064894 0.85 ALOX15 (0.72) ALOX15MAPTSMN1; SMN2KDM4EALDH1A1
SCHEMBL25918382 0.85 SDCBP (0.55) ALOX15MAPTSMN1; SMN2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240317729-A1 Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2024-09-26 US disclosed
US-10730862-B2 Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligase YALE UNIVERSITY (US) 2020-08-04 US disclosed
US-10730862-B2 Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligase YALE UNIVERSITY (US) 2020-08-04 US disclosed
EP-3608317-A1 COMPOUNDS & METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS & OTHER POLYPEPTIDES BY AN E3 UBIQUITIN LIGASE Yale University (US) 2020-02-12 EP disclosed
US-20190127359-A1 Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase UNIV YALE (US) 2019-05-02 US disclosed
US-20190127359-A1 Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase UNIV YALE (US) 2019-05-02 US disclosed
US-20140356322-A1 Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2014-12-04 US disclosed
US-20140356322-A1 Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2014-12-04 US disclosed
US-20140356322-A1 Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2014-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10730862-B2 Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligase VHL, MDM2, NEDD4 ALOX15 4623/4885MAPT 2486/4885SMN1; SMN2 3696/4885
US-20140356322-A1 Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase VHL, MDM2, STUB1 ALOX15 4593/4885MAPT 2247/4885SMN1; SMN2 4103/4885
US-20190127359-A1 Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase MDM2, VHL, XIAP ALOX15 4587/4885MAPT 2444/4885SMN1; SMN2 4118/4885
US-20240317729-A1 Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase MDM2, VHL, XIAP ALOX15 4587/4885MAPT 2444/4885SMN1; SMN2 4118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.